Malaria is a disease caused by protozoans transmitted to humans by infected female Anopheles mosquitoes. According to the WHO\nreport of 2015, there were 214 million cases of malaria with 438,000 deaths worldwide. Ninety percent of worldâ??s malaria cases occur\nin Africa, where the disease is recognized as a serious impediment to economic and social development. Despite advancement in\nmalaria research, the disease continues to be a global problem, especially in developing countries. Currently, there is no effective\nvaccine for malaria control. In addition, although there are effective drugs for treatment of malaria, this could be lost to the drug\nresistance in different Plasmodium species. The most lethal form is caused by P. falciparum which has developed resistance to many\nchemotherapeutic agents and possibly to the current drugs of choice. Reducing the impact of malaria is a key to achieving the\nsustainable development goals which are geared toward combating the disease. Covalent bitherapy is a rational and logical way of\ndrug design which entails joining a couple of molecules with individual intrinsic action into a unique agent, hence packaging dual\nactivity into one hybrid. This suggests the need to develop new antimalarial drugs that are effective against malaria parasites based on\nthe new mode of action, molecular targets, and chemical structures. In silico studies have shown that sarcosine is able to bind to\nunique plasmodia proteins (P. falciparum ATCase), whereas aniline can be a ligand to target protein (enoyl acyl carrier protein\nreductase), hence suppressing the progression of the disease. The main objective of this study was to synthesize and determine the\nefficacy and safety of antiplasmodial hybrid drug comprising the sarcosine and aniline derivative...................
Loading....